Effect of dapson in treatment of pemphigus vulgaris

Evaluation of therapeutic effect of prednisolone + dapson with prednisolone+imurane in pemphigus vulgaris treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307133566N2

Enrollment

Registered

2013-08-03

Start date

2012-09-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus vulgaris. Pemphigus vulgaris

Interventions

Intervention 1: control: treatment by prednisolone+imurane prednisolone 1-2mg/kg/day imurane:2-3mg/kg/day. Intervention 2: Interventionaris treatment by prednisolone + dapson prednisolone 1-2mg/kg

Treatment - Drugs

control: treatment by prednisolone+imurane prednisolone 1-2mg/kg/day imurane:2-3mg/kg/day

Interventionaris treatment by prednisolone + dapson prednisolone 1-2mg/kg /day dapson100-200mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion: patients with pemphigus vulgaris, that their disease was detected by the clinical or pathological evidence of initial tests with pemphigus vulgaris. Exclusion criterion: patients who were G6PDD.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of damage. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Physical examination.	—

Secondary

Measure	Time frame
Lipid profile. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Lab tests.;HTN. Timepoint: the patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: lab.;Liver function test. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Lab tests.	—

Measure

Time frame

Lipid profile. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Lab tests.;HTN. Timepoint: the patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: lab.;Liver function test. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Lab tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamide Azimi

Tabriz university of medical sciences

azimi@tbzmed.ac.ir+98 41 1540 6612

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026